338 related articles for article (PubMed ID: 24363993)
1. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Shelkovnikov S; Farzaneh SH; Khazaeli M; Meyer CJ
Redox Biol; 2013; 1(1):527-31. PubMed ID: 24363993
[TBL] [Abstract][Full Text] [Related]
2. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Khazaeli M; Yuan J; Meyer CJ
Xenobiotica; 2014 Jun; 44(6):570-8. PubMed ID: 24195589
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease.
Vaziri ND; Liu S; Farzaneh SH; Nazertehrani S; Khazaeli M; Zhao YY
Free Radic Biol Med; 2015 Sep; 86():374-81. PubMed ID: 25930007
[TBL] [Abstract][Full Text] [Related]
4. The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling.
Bubb KJ; Kok C; Tang O; Rasko NB; Birgisdottir AB; Hansen T; Ritchie R; Bhindi R; Reisman SA; Meyer C; Ward K; Karimi Galougahi K; Figtree GA
Free Radic Biol Med; 2017 Jul; 108():585-594. PubMed ID: 28438659
[TBL] [Abstract][Full Text] [Related]
5. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction.
Sharma A; Rizky L; Stefanovic N; Tate M; Ritchie RH; Ward KW; de Haan JB
Cardiovasc Diabetol; 2017 Mar; 16(1):33. PubMed ID: 28253885
[TBL] [Abstract][Full Text] [Related]
6. Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.
Ichikawa T; Li J; Meyer CJ; Janicki JS; Hannink M; Cui T
PLoS One; 2009 Dec; 4(12):e8391. PubMed ID: 20027226
[TBL] [Abstract][Full Text] [Related]
7. Dihydro-CDDO-trifluoroethyl amide suppresses inflammatory responses in macrophages via activation of Nrf2.
Li B; Abdalrahman A; Lai Y; Janicki JS; Ward KW; Meyer CJ; Wang XL; Tang D; Cui T
Biochem Biophys Res Commun; 2014 Feb; 444(4):555-61. PubMed ID: 24486487
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Triterpenoid RTA dh404 (CDDO-dhTFEA) Ameliorates Acute Pancreatitis.
Robles L; Vaziri ND; Li S; Masuda Y; Takasu C; Takasu M; Vo K; Farzaneh SH; Stamos MJ; Ichii H
Pancreas; 2016; 45(5):720-9. PubMed ID: 26495793
[TBL] [Abstract][Full Text] [Related]
9. Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption.
Lau WL; Liu SM; Pahlevan S; Yuan J; Khazaeli M; Ni Z; Chan JY; Vaziri ND
Dig Dis Sci; 2015 May; 60(5):1215-22. PubMed ID: 25399330
[TBL] [Abstract][Full Text] [Related]
10. Triterpenoid dihydro-CDDO-trifluoroethyl amide protects against maladaptive cardiac remodeling and dysfunction in mice: a critical role of Nrf2.
Xing Y; Niu T; Wang W; Li J; Li S; Janicki JS; Ruiz S; Meyer CJ; Wang XL; Tang D; Zhao Y; Cui T
PLoS One; 2012; 7(9):e44899. PubMed ID: 23028668
[TBL] [Abstract][Full Text] [Related]
11. CDDO-9,11-dihydro-trifluoroethyl amide (CDDO-dhTFEA) induces hepatic cytoprotective genes and increases bile flow in rats.
Reisman SA; Ward KW; Klaassen CD; Meyer CJ
Xenobiotica; 2013 Jul; 43(7):571-8. PubMed ID: 23244591
[TBL] [Abstract][Full Text] [Related]
12. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure.
Kim HJ; Vaziri ND
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F662-71. PubMed ID: 20007347
[TBL] [Abstract][Full Text] [Related]
13. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy.
Aminzadeh MA; Nicholas SB; Norris KC; Vaziri ND
Nephrol Dial Transplant; 2013 Aug; 28(8):2038-45. PubMed ID: 23512109
[TBL] [Abstract][Full Text] [Related]
14. Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease.
Tan SM; Sharma A; Stefanovic N; Yuen DY; Karagiannis TC; Meyer C; Ward KW; Cooper ME; de Haan JB
Diabetes; 2014 Sep; 63(9):3091-103. PubMed ID: 24740568
[TBL] [Abstract][Full Text] [Related]
15. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Nezu M; Suzuki N; Yamamoto M
Am J Nephrol; 2017; 45(6):473-483. PubMed ID: 28502971
[TBL] [Abstract][Full Text] [Related]
16. Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway.
Soetikno V; Sari FR; Lakshmanan AP; Arumugam S; Harima M; Suzuki K; Kawachi H; Watanabe K
Mol Nutr Food Res; 2013 Sep; 57(9):1649-59. PubMed ID: 23174956
[TBL] [Abstract][Full Text] [Related]
17. The effect of Nrf2 pathway activation on human pancreatic islet cells.
Masuda Y; Vaziri ND; Li S; Le A; Hajighasemi-Ossareh M; Robles L; Foster CE; Stamos MJ; Al-Abodullah I; Ricordi C; Ichii H
PLoS One; 2015; 10(6):e0131012. PubMed ID: 26110640
[TBL] [Abstract][Full Text] [Related]
18. Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function.
Nagasu H; Sogawa Y; Kidokoro K; Itano S; Yamamoto T; Satoh M; Sasaki T; Suzuki T; Yamamoto M; Wigley WC; Proksch JW; Meyer CJ; Kashihara N
FASEB J; 2019 Nov; 33(11):12253-12263. PubMed ID: 31431054
[TBL] [Abstract][Full Text] [Related]
19. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease.
Ruiz S; Pergola PE; Zager RA; Vaziri ND
Kidney Int; 2013 Jun; 83(6):1029-41. PubMed ID: 23325084
[TBL] [Abstract][Full Text] [Related]
20. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).
Impellizzeri D; Esposito E; Attley J; Cuzzocrea S
Pharmacol Res; 2014 Mar; 81():91-102. PubMed ID: 24602801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
